This site is intended for healthcare professionals

Three-year data from CheckMate -227 confirms durable, long-term survival benefit for Opdivo + Yervoy in metastatic first-line non-small cell lung cancer .- BMS

Read time: 1 mins
Last updated:16th Mar 2021
Published:15th May 2020
Condition: Non Small Cell Lung Cancer
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest